Mar 13, 2026 06:10AM H.C. Wainwright Reiterates Buy Rating on Candel Therapeutics Inc. (CADL)

Mar 12, 2026 03:57PM Candel Therapeutics, Inc. (CADL) Misses Q4 EPS by 29c

Feb 19, 2026 04:02PM Candel Therapeutics secures $100M royalty funding deal with RTW

Nov 21, 2025 12:24PM Candel Therapeutics Inc. (CADL) PT Raised to $14 at Freedom Capital Markets

Nov 13, 2025 04:50PM Candel Therapeutics, Inc. (CADL) Misses Q3 EPS by 3c

Nov 4, 2025 09:00AM Candel Therapeutics to present phase 3 prostate cancer trial results at SITC

Oct 27, 2025 04:36PM Stephens Starts Candel Therapeutics Inc. (CADL) at Overweight

Oct 21, 2025 06:41AM LifeSci Capital Starts Candel Therapeutics Inc. (CADL) at Outperform

Oct 14, 2025 08:12AM Candel Therapeutics secures $130 million term loan facility with Trinity Capital

Oct 14, 2025 08:07AM Candel Therapeutics reports interim data on CAN-3110 for glioblastoma

Oct 7, 2025 06:47AM H.C. Wainwright Reiterates Buy Rating on Candel Therapeutics Inc. (CADL)

Sep 30, 2025 06:53AM H.C. Wainwright Reiterates Buy Rating on Candel Therapeutics Inc. (CADL)

Aug 14, 2025 04:18PM Candel Therapeutics, Inc. (CADL) Tops Q2 EPS by 7c

Aug 14, 2025 08:44AM Candel Therapeutics (CADL) Files $300M Mixed Shelf

Jul 24, 2025 08:06AM Candel receives EMA orphan designation for pancreatic cancer drug

Jul 14, 2025 06:16AM Freedom Broker Starts Candel Therapeutics Inc. (CADL) at Buy

Jul 9, 2025 04:46PM Brookline Capital Markets Starts Candel Therapeutics Inc. (CADL) at Buy

Jul 9, 2025 08:08AM Candel Therapeutics added to five Russell value indexes

Jun 30, 2025 06:41AM H.C. Wainwright Assumes Candel Therapeutics Inc. (CADL) at Buy

Jun 24, 2025 09:06AM Candel Therapeutics (CADL) Announces $15 million Registered Direct Offering of Common Stock

Jun 23, 2025 08:05AM Candel Therapeutics (CADL) Appoints Charles Schoch as CFO

Jun 6, 2025 08:07AM Candel Therapeutics (CADL) Appoints Maha Radhakrishnan to its Board

May 28, 2025 08:05AM Candel Therapeutics (CADL) Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer

May 22, 2025 05:08PM Candel Therapeutics (CADL) offers positive results from Phase 3 CAN-2409 trial

May 13, 2025 05:11PM Candel Therapeutics, Inc. (CADL) Tops Q1 EPS by 50c

Apr 23, 2025 04:13PM Candel Therapeutics (CADL) Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

Apr 11, 2025 06:38AM H.C. Wainwright Reiterates Buy Rating on Candel Therapeutics Inc. (CADL)

Apr 1, 2025 08:02AM Candel Therapeutics (CADL) Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care

Mar 26, 2025 04:05PM Candel Therapeutics (CADL) Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409

Mar 20, 2025 08:01AM Candel Therapeutics (CADL) and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409

Mar 17, 2025 06:43AM H.C. Wainwright Reiterates Buy Rating on Candel Therapeutics Inc. (CADL)

Feb 25, 2025 08:01AM Candel Therapeutics (CADL) Announces Positive Final Survival Data from Phase 2 Trial of CAN-2409

Feb 20, 2025 05:01AM Citi Starts Candel Therapeutics Inc. (CADL) at Buy, PT $25

Jan 13, 2025 08:16AM Candel Therapeutics (CADL) Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025

Dec 18, 2024 06:45AM Candel Therapeutics Inc. (CADL) PT Raised to $19 at H.C. Wainwright

Dec 13, 2024 07:32AM Candel Therapeutics (CADL) Prices Public Offering

Dec 12, 2024 04:55PM After-hours movers: Broadcom, Costco, EVgo, Candel Therapeutics

Dec 12, 2024 04:52PM Candel Therapeutics (CADL) Announces $80 Million Proposed Public Offering

Dec 11, 2024 03:12PM Candel Therapeutics (CADL) call put ratio 1 call to 1.3 puts with a focus on December options as share price up 84%

Dec 11, 2024 07:30AM Candel Therapeutics (CADL) Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival

Aug 13, 2024 08:21AM Candel Therapeutics, Inc. (CADL) Reports Q2 Loss of $0.74/sh

Jun 11, 2024 08:03AM Candel Therapeutics (CADL) to Join Russell 3000 Index